Overview

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

Status:
Active, not recruiting
Trial end date:
2022-05-05
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the percentage of participants who are hospitalized and/or die through Day 29
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.